3-[[(4-aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as dopamine D2 partial agonists and autoreceptor agonists

Journal of Medicinal Chemistry

Volumn 40, Issue 2, 1997, Pages 250-259

  Wustrow, David J ^a   Smith III, William J ^a   Corbin, Ann E ^a   Davis, M Duff ^a   Georgic, Lynn M ^a   Pugsley, Thomas A ^a   Whetzel, Steven Z ^a   Heffner, Thomas G ^a   Wise, Lawrence D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[4 (1H 3 INDOLYL)CYCLOHEXYL]ETHYL] 4 (2 PYRIDINYL)PIPERAZINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE AUTORECEPTOR; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SQUIRREL MONKEY; STEREOCHEMISTRY; STEREOTYPY; STRUCTURE ACTIVITY RELATION; SUBSTANTIA NIGRA;

ANIMALS; AUTORECEPTORS; BEHAVIOR, ANIMAL; CHO CELLS; CRICETINAE; CYCLOHEXANES; DOPAMINE AGONISTS; HUMANS; INDOLES; KINETICS; MALE; MICE; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SAIMIRI;

EID: 0031022285     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960597m     Document Type: Article

References (46)

1. (1) Seeman, P. Dopamine Receptors and the Dopamine Hypothesis of Schizophrenia. Synapse 1987, 1, 133-152. Carlsson, A. The Current Satus of the Dopamine Hypothesis of Schizophrenia. Neuropsychopharmacology 1988, 1, 179-186.
2. Seeman, P. Dopamine Receptors and the Dopamine Hypothesis of Schizophrenia. Synapse 1987, 1, 133-152. Carlsson, A. The Current Satus of the Dopamine Hypothesis of Schizophrenia. Neuropsychopharmacology 1988, 1, 179-186.
3. Roth R. H. Dopamine Autoreceptors: Pharmacology, Function and Comparison with Postsynaptic Dopamine Receptors. Commun. Psychopharmacol. 1979, 3, 429-445.
4. (a) Tamminga, C. A.; Gotts, M. D.; Thaker, G. K.; Alpha, L. D.; Foster, N. L. Dopamine Agonist Treatment of Schizophrenia with N-propyl-norapomorphine. Arch., Gen. Psychiatry 1986, 43, 398-402.
5. (b) Tamminga, C. A.; Schaffer, M. H.; Smith, R. C.; Davis, J. M. Schizophrenia Symptoms Improve with Apomorphine. Science 1978, 200, 567-8.
6. (c) Hollister, L. E.; Davis, K. L.; Berger, P. A. Apomorphine in Schizophrenia Commun. Psychopharmacol. 1980, 4, 277-281.
7. Meltzer, H. Y. Relevance of Dopamine Autoreceptors for Psychiatry: Preclinical and Clinical Studies. Schizophr. Bull. 1980, 6, 456-75.
8. (a) Sokoloff, P.; Giros, B.; Martres, M. P.; Andrieux, M., Besancon, R.; Pilon, C.; Bouthenent, M. L.; Souil, E.; Schwartz, J. C. Localization and Function of the D3 Dopamine Receptor. Arzneim.-Forsch./Drug Res. 1992, 42, 224-230.
9. (b) Meller, E.; Bohmaker, K.; Goldstein, M.; Basham, D. A. Evidence that Striatal Synthesis Inhibiting Autoreceptors are Dopamine D3 Receptors. Eur. J. Pharmacol. 1993, 249, R5-R6.
10. (a) Tang, L.; Todd, R. D.; O'Malley, K. L. Dopamine D2 and D3 Receptors Inhibit Dopamine Release J. Pharmacol. Exp. Ther. 1994, 270, 475-9.
11. (b) Gainetdinov, R. R.; Sotnikova, T. D.; Grekhova, T. V.; Rayevsky, K. S. In Vivo Evidence for Preferential Role of Dopamine D3 Receptor in the Presynaptic Regulation of Dopamine Release but not Synthesis. Eur. J. Pharmacol. 1996, 308, 261-9.
12. (a) Waters, N.; Svensson, K.; Haadsma-Svensson, S. R.; Smith, M. W.; Carlson, A. The Dopamine D3-Receptor: A Postsynaptic Receptor Inhibitory on Rat Locomotor Activity. J. Neural Transm. 1993, 94, 11-19.
13. (b) Gifford, A. N.; Johnson, A. Pharmacological Analysis of the Effect of (+)-AJ 76 and (+)-UH 232 at Release Regulating Pre- and Postsynaptic Dopamine Receptors. Eur. J. Pharmacol. 1993, 237, 169-175.
14. (c) Svensson, K.; Carlson, A.; Waters, N. Locomotion Inhibition by D3 Ligand R(+)-7-OH-DPAT is Independent of Changes in Dopamine Release. J. Neural Transm. 1994, 95, 71-74.
15. Helmreich, I.; Reimann, W.; Hertting, G.; Starke, K. Are Presynaptic Dopamine Autoreceptors and Postsynaptic Dopamine Receptors in the Rabbit Caudate Nucleus Pharmacologically Different? J. Neurosci. 1982, 7, 1559-1566.
16. (a) Carlsson, A.; Dopamine Receptor Agonists: Intrinsic Activity vs State of Receptor. J. Neural Transm. 1983, 57, 309-315.
17. (b) Meiler, E.; Bohmaker, K.; Namba, Y.; Friedhoff, A. J.; Goldstein, M. Relationship Between Receptor Occupancy and Response at Striatal Dopamine Autoreceptors. Mol. Pharmacol. 1987, 31, 592-598.
18. (c) Meller, E., Enz, A.; Goldstein, M. Absence of Receptor Reserve at Striatal Dopamine Receptors Regulating Cholinergic Neuronal Activity. Eur. J. Pharmacol. 1988, 155, 151-154.
19. Wise, L. D.; Jaen, J. C. Design of Orally Active Dopamine Autoreceptor Agonists. In Drugs Design for Neuroscience; Kozikowski, A. P., Ed.; Raven Press: New York, 1993; p 119.
20. (a) Böttcher H.; Barnickel, G.; Hausberg, H.-H.; Haase, A. F.; Seyfried, C. A.; Eiermann, V. Synthesis and Dopaminergic Activity of Some 3-(1,2,3,6-Tetrahydro-1-pyridylalkyl)indoles. A Novel Conformational Model To Explain Structure-Activity Relationships. J. Med. Chem. 1992, 35, 4020-4026.
21. (b) Bartoszyk, G. D.; Harting, J.; Minck, K.-O. Roxindole: Psychopharmacological Profile of a Dopamine D2 Autoreceptor Agonist. J. Pharmacol. Exp. Ther. 1996, 276, 41-8.
22. Jaen, J. C.; Wise, L. D.; Heffner, T. G.; Pugsley, T. A.; Meltzer, L. T. Dopamine Autoreceptor Agonists as Potential Antipsychotics. 2. (Aminoalkoxy)-4H-1benzopyran-4-ones. J. Med. Chem. 1991, 34, 248-256.
23. (a) Wright, J. L.; Caprathe, B. W.; Downing, D. M.; Glase, S. A.; Heffner, T. G.; Jaen, J. C.; Johnson, S. J.; Kesten, S. R.; MacKenzie, R. G.; Meltzer, L. T.; Pugsley, T. A.; Smith, S. J.; Wise, L. D.; Wustrow, D. J. The Discovery and Structure-Activity Relationships of 1,2,3,6-Tetrahydro-4-phenyl-1- [(arylcyclohexenyl)alkyl]pyridines. Dopamine Autoreceptor Agonists and Potential Antipsychotic Agents. J. Med. Chem. 1994, 37, 3523-33.
24. (b) Pugsley, T. A.; Davis, M. D.; Akunne, H. C.; Cooke, L. W.; Whetzel, S. Z.; Mackenzie, R. G.; Shih, Y.-H.; Van Leeuwen, D. H.; Demattos, S. B.; Georgie, L. M.; Caprathe, B. W.; Wright, J. C.; Jaen, J. C.; Wise, L. D.; Heffner, T. G. CI-1007, a Dopamine Partial Agonist and Potential Antipsychotic Agent. I. Neurochemical Effects. J. Pharmacol. Exp. Ther. 1995, 274, 898-911.
25. (c) Meltzer, L. T.; Christoffersen, C. L.; Corbin, A. E.; Nineteman, F. W.; Serpa, K. A.; Wiley, J. N.; Wise, L. D.; Heffner, T. G. CI-1007, a Dopamine Partial Agonist and Potential Antipsychotic Agent. II. Neurophysiological and Behavioral Effects. J. Pharmacol. Exp. Ther. 1995, 274, 912-920.
26. Jaen, J. C.; Caprathe, B. W.; Wise, L. D.; Meltzer, L. T.; Pugsley, T. A.; Heffner, T. G. Synthesis and Pharmacological Evaluation of The Enantiomers of The Dopamine Autoreceptor Agonist PD 135385. Bioorg. Med. Chem. Lett. 1993, 3, 639-44.
27. (15) Heaney, H.; Ley, S. V. 1-Benzylindole. Organic Syntheses; Wiley: New York, 1988; Collect. Vol. VI, pp 104-5; Heaney, H.; Ley, S. V. N-Alkylation of Indole and Pyrroles in Dimethyl Sulfoxide J. Chem. Soc., Perkin Trans, 1 1973, 499-500.
28. Heaney, H.; Ley, S. V. 1-Benzylindole. Organic Syntheses; Wiley: New York, 1988; Collect. Vol. VI, pp 104-5; Heaney, H.; Ley, S. V. N-Alkylation of Indole and Pyrroles in Dimethyl Sulfoxide J. Chem. Soc., Perkin Trans, 1 1973, 499-500.
29. (a) Pugsley, T. A.; Christoferson, C. L.; Corbin, A.; DeWald, H. A.; Demattos, S.; Meltzer, L. T.; Myers, S. L. Shih, Y.-H.; Whetzel, S. Z.; Wiley, J. N.; Wise, L. D.; Heffner, T. G.; Pharmacological Characterization of PD 118717, A Putative Piperazinyl Benzopyranone Dopamine Autoreceptor Agonist. J. Pharmacol. Exp. Ther. 1992, 263, 1147-1155.
30. (b) Grigoriadis, D.; Seeman, P. Complete Conversion of Brain D-2 Dopamine recptors from High to Low Affinity States for Dopamine Agonists Using Sodium and Guanine Nucleotides. J. Neurochem. 1985, 44, 1925-1935.
31. (a) Strombom, U. Catecholamine Receptor Agonists. Naunyn-Schmiedeberg's Arch. Pharmacol 1976, 292, 167-176.
32. (b) Martin, G. E.; Bendesky, R. J. Mouse Locomotor Activity: An In Vivo Test for Dopamine Autoreceptor Activation J. Pharmacol. Exp. Ther. 1984, 229, 706.
33. (c) Heffner, T. G.; Downs, D. A.; Meltzer, L. T.; Wiley, J. N.; Williams, A. E. CI-943, A Potential Antipsychotic Agent I. Preclinical Behavioral Effects. J. Pharmacol. Exp. Ther. 1989, 251, 105-112.
34. Walters, J. R.; Roth, R. H. Dopaminergic Neurons: Alteration in the Sensitivity of Tyrosine Hydroxylase to Inhibition by Endogenous Dopamine after Cessation of Impulse Flow. Biochem. Pharmacol. 1976, 25, 649-654.
35. 18. Seeman, P.; Wataanabe, M.; Grigoriadis, D.; Tedesco, J. L.; Goerge, S. R.; Svennson, U.; Nilsson, J. L. G.; Neumeyer, J. L. Dopamine D2 Receptor Binding Sites for Agonists: A Tetrahedral Model. Mol. Pharmacol. 1989, 160, 31-41.
36. MacKenzie, R. G.; Van Leeuwen, D.; Pugsley, T. A.; Shih, Y.-H.; DeMattos, S.; Tang, L.; Todd, R. D.; O'Malley, K. L. Characterization of Human D3 Receptor Expressed in Transfected Cell Lines. Eur. J. Pharmacol. - Mol. Pharmacol. 1993, 266, 785-89.
37. Shih, Yu Hsin; Akunne, H. C.; Zoski, K.; Georgie, L. M.; Pugsley, T. A. Interaction of BMY 14802 with Subtypes of Dopamine Receptors. Pharmacol. Commun. 1996, 7, 243-250.
38. Lajiness, M. E.; Chio, C. L.; Huff, R. M. D2 Dopamine Receptor Stimulation of Mitogenesis in Transfected Chinese Hamster Ovary Cells: Relationship to Dopamine Stimulation of Tyrosine Phosphorylations. J. Pharmacol. Exp. Ther. 1993, 267, 1573-1581.
39. (a) Bunney, B. S.; Walters, J. R.; Roth, R. H.; Aghajanian, G. K. Dopaminergic Neurons: Effect of Antipsychotic Drugs and Amphetamine on Single Cell Activity. J. Pharmacol. Exp. Ther. 1973, 185, 560-571.
40. (b) Bunney, B. S.; Aghajanian, G. K.; Roth, R. H. Comparison of Effects of L-Dopa, Amphetamine and Apomorphine on Firing Rate of Dopaminergic Neurons. Nature (London) 1973, 245, 123-1255.
41. Protais, P.; Constentin, J.; Schwartz, J. Climbing Behavior Induced by Apomorphine in Mice Psychopharmacology 1976, 50, 1-6.
42. Meltzer, L. T.; Caprathe, B. W.; Christoffersen, C. L.; Corbin, A. E.; Jaen, J. C.; Ninteman, F. W.; Pugsley, T. A.; Serpa, K. A.; Shih, Y.-H.; Wiley, J. N.; Wise, L. D.; Heffner, T. G. Pharmacological Profile of the Dopamine Partial Agonist, (±) PD-128483 and Its Enantiomers. J. Pharmacol. Exp. Ther. 1993, 266, 1177-1189.
43. (a) Sidman M. Two Temporal Parameters of the Maintenance of Avoidance Behavior in the White Rat. J. Comput. Physiol. Psychol. 1953, 46, 253-261.
44. (b) Sidman M. Avoidance Conditioning with Brief Shock and No Exteroceptive Warning Signal. Science 1953, 118, 157-8.
45. (c) Heise, G.; Boff, E. Continuous Avoidance as a Base-Line for Measuring Behavioral Effects of Drugs Psychopharmacologia 1962, 3, 264-282.
46. Glase, S. A.; Akunne, H. C.; Heffner, T. G.; Jaen, J. C.; MacKenzie, R. G.; Meltzer, L. T.; Pugsley, T. A.; Smith, S. J.; Wise, L. D. Aryl 1-Butynyl-4-phenyl-1,2,3,6-tetrahydropyridines as Potential Antipsychotic Agents: Synthesis and Structure-Activity Relationships. J. Med. Chem. 1996, 39, 3179-3187.